Havrix, 1440 units 1 ml

Havrix provides active immunity against hepatitis A virus for at least 15-20 years (when using a two-dose vaccination schedule).

In clinical researches it was found that antibodies to hepatitis A antigen on the 15th day after vaccination in persons 18-50 years old are formed in 88% of cases, 1-18 years old – in 93% of cases; one month after vaccination – in 99% of cases in both age groups. Vaccine application is effective in the early incubation period of the disease.

The effectiveness of the vaccine is not reduced in case of presence of maternal antibodies to hepatitis A virus or antibodies to hepatitis A virus introduced passively in the blood of the vaccinated person.

Indications

Active immunoprophylaxis for hepatitis A.

Active ingredient

Vaccine to prevent viral hepatitis A

Composition

1 dose of suspension for injection for adults contains:

acting substance:

Hepatitis A viral antigen 1440 units (determination by ELISA solid phase immunoassay)

How to take, the dosage

Havrix is given intramuscularly. Adults over 19 years of age: 1440 IU (1 ml) in the deltoid region.

A 6 to 12 months after the first vaccination it is recommended that it be repeated.

Patients with thrombocytopenia or clotting disorders are injected subcutaneously.

Interaction

Mixing with other vaccines in the same syringe is not allowed.

Compatible with all vaccines in the Russian National Vaccine Calendar and all travel vaccines.

Special Instructions

If Xavrix is administered simultaneously with other vaccines, injections should be given at different sites.

In patients on hemodialysis and those with severe immunodeficiency, antibody formation to the hepatitis A antigen after a single dose of vaccine may be insufficient, so additional doses are recommended for these patients.

Contraindications

Hypersensitivity to any of the components of the vaccine.

Acute and chronic inflammatory diseases accompanied by fever (vaccination is postponed until the normalization of body temperature).

Side effects

Local:~ 4% of cases – swelling, redness at the injection site;

Systemic: 0.8-12.8% of cases – headache, malaise, nausea, vomiting, loss of appetite (no treatment, lasts less than 24 hours).

Pregnancy use

Only if absolutely necessary.